$HURA
DELMAR PHARMACEUTICALS, INC.

2023 Q3 Form 10-K Financial Statement

#000095017023048588 Filed on September 18, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.100M $1.270M $5.490M
YoY Change -25.42% -12.65% -26.89%
% of Gross Profit
Research & Development $1.859M $2.080M $9.311M
YoY Change -41.37% -48.05% -38.63%
% of Gross Profit
Depreciation & Amortization $15.00K $10.00K $60.00K
YoY Change 0.0% -33.33% 0.0%
% of Gross Profit
Operating Expenses $2.962M $3.350M $14.80M
YoY Change -36.25% -38.62% -34.77%
Operating Profit
YoY Change
Interest Expense $0.00 $10.00K $150.0K
YoY Change -100.0% -16.67% 614.29%
% of Operating Profit
Other Income/Expense, Net $0.00 $147.0K
YoY Change -100.0% 600.0%
Pretax Income -$2.960M -$3.340M -$14.65M
YoY Change -35.6% -38.67% -35.35%
Income Tax
% Of Pretax Income
Net Earnings -$2.962M -$3.340M -$14.65M
YoY Change -35.55% -38.67% -35.36%
Net Earnings / Revenue
Basic Earnings Per Share -$1.83 -$9.27
Diluted Earnings Per Share -$1.83 -$1.97 -$9.27
COMMON SHARES
Basic Shares Outstanding 1.746M 1.692M 1.620M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $220.0K $1.540M $1.540M
YoY Change -96.89% -86.93% -86.93%
Cash & Equivalents $216.0K $1.535M $1.540M
Short-Term Investments
Other Short-Term Assets $570.0K $1.740M $1.740M
YoY Change -46.78% 17.73% 17.73%
Inventory
Prepaid Expenses $567.0K $660.0K
Receivables
Other Receivables
Total Short-Term Assets $783.0K $3.270M $3.270M
YoY Change -90.4% -75.34% -75.34%
LONG-TERM ASSETS
Property, Plant & Equipment $694.0K $709.0K $710.0K
YoY Change -7.96% 687.78% 688.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $694.0K $709.0K $710.0K
YoY Change -86.27% -73.64% -73.61%
TOTAL ASSETS
Total Short-Term Assets $783.0K $3.270M $3.270M
Total Long-Term Assets $694.0K $709.0K $710.0K
Total Assets $1.477M $3.979M $3.980M
YoY Change -88.82% -75.05% -75.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.000M $2.780M $2.780M
YoY Change 1.94% -14.96% -14.96%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.336M $3.082M $3.080M
YoY Change -5.12% -22.76% -22.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $170.0K $170.0K $170.0K
YoY Change 123.68% 4.29% 4.29%
Total Long-Term Liabilities $170.0K $170.0K $170.0K
YoY Change 123.68% 4.29% 4.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.336M $3.082M $3.080M
Total Long-Term Liabilities $170.0K $170.0K $170.0K
Total Liabilities $3.503M $3.248M $3.250M
YoY Change -2.48% -21.79% -21.74%
SHAREHOLDERS EQUITY
Retained Earnings -$154.5M -$151.4M
YoY Change 9.34% 11.01%
Common Stock $141.9M $141.4M
YoY Change 2.53% 4.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.026M $731.0K $730.0K
YoY Change
Total Liabilities & Shareholders Equity $1.477M $3.979M $3.980M
YoY Change -88.82% -75.05% -75.04%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023
OPERATING ACTIVITIES
Net Income -$2.962M -$3.340M -$14.65M
YoY Change -35.55% -38.67% -35.36%
Depreciation, Depletion And Amortization $15.00K $10.00K $60.00K
YoY Change 0.0% -33.33% 0.0%
Cash From Operating Activities -$1.317M -$1.510M -$11.87M
YoY Change -79.32% -69.75% -41.82%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $230.0K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$232.0K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000K 0.000 1.852M
YoY Change -100.1% -100.0% -91.44%
NET CHANGE
Cash From Operating Activities -1.317M -1.510M -11.87M
Cash From Investing Activities 0.000 0.000 -232.0K
Cash From Financing Activities -2.000K 0.000 1.852M
Net Change In Cash -1.319M -1.510M -10.25M
YoY Change -71.91% -151.34% -924.22%
FREE CASH FLOW
Cash From Operating Activities -$1.317M -$1.510M -$11.87M
Capital Expenditures $0.00 $0.00 $230.0K
Free Cash Flow -$1.317M -$1.510M -$12.10M
YoY Change -81.78% -69.75% -40.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001498382
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Open Tax Year
OpenTaxYear
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Open Tax Year
OpenTaxYear
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37823
CY2023 dei Entity Registrant Name
EntityRegistrantName
Kintara Therapeutics, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0360497
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
9920 Pacific Heights Blvd
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 150
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2023 dei City Area Code
CityAreaCode
858
CY2023 dei Local Phone Number
LocalPhoneNumber
350-4364
CY2023 dei Security12b Title
Security12bTitle
Common Stock
CY2023 dei Trading Symbol
TradingSymbol
KTRA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
11500
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1746408
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, CA
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1535000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11780000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
660000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1478000
CY2023Q2 ktra Clinical Trial Deposit Current
ClinicalTrialDepositCurrent
1075000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
3270000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
13258000
CY2022Q2 ktra Clinical Trial Deposit Non Current
ClinicalTrialDepositNonCurrent
2600000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
709000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90000
CY2023Q2 us-gaap Assets
Assets
3979000
CY2022Q2 us-gaap Assets
Assets
15948000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2784000
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3269000
CY2023Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
298000
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
721000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3082000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3990000
CY2023Q2 ktra Milestone Payment Liability
MilestonePaymentLiability
166000
CY2022Q2 ktra Milestone Payment Liability
MilestonePaymentLiability
163000
CY2023Q2 us-gaap Liabilities
Liabilities
3248000
CY2022Q2 us-gaap Liabilities
Liabilities
4153000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5500000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1692000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1311000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
141438000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
135575000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151375000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136356000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
731000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
11795000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3979000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15948000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9311000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15173000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5485000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7509000
CY2023 us-gaap Operating Expenses
OperatingExpenses
14796000
CY2022 us-gaap Operating Expenses
OperatingExpenses
22682000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
10000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7000
CY2023 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
137000
CY2022 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
14000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
147000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14649000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-22661000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14649000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-22661000
CY2023 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
8000
CY2022 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
8000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15019000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25131000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.27
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-25.80
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1620000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
974000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
10581000
CY2022 ktra Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
21526000
CY2022 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
35000
CY2022 ktra Exercise Of2020 Investor Warrants For Cash
ExerciseOf2020InvestorWarrantsForCash
69000
CY2022 ktra Exercise Of Pre Funded Warrants For Cash
ExerciseOfPreFundedWarrantsForCash
5000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2283000
CY2022 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-43000
CY2022 us-gaap Profit Loss
ProfitLoss
-22661000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
11795000
CY2023 ktra Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
1903000
CY2023 ktra Issuance Of Shares For Services
IssuanceOfSharesForServices
110000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1490000
CY2023 ktra Adjustments To Additional Paid In Capital Restricted Stock Unit Expense
AdjustmentsToAdditionalPaidInCapitalRestrictedStockUnitExpense
90000
CY2023 ktra Series Preferred Stock Dividends
SeriesPreferredStockDividends
-8000
CY2023 us-gaap Profit Loss
ProfitLoss
-14649000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
731000
CY2023 us-gaap Profit Loss
ProfitLoss
-14649000
CY2022 us-gaap Profit Loss
ProfitLoss
-22661000
CY2023 us-gaap Depreciation
Depreciation
60000
CY2022 us-gaap Depreciation
Depreciation
60000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3225000
CY2023 ktra Gain Loss From Change In Fair Value Of Milestone Liability
GainLossFromChangeInFairValueOfMilestoneLiability
-3000
CY2022 ktra Gain Loss From Change In Fair Value Of Milestone Liability
GainLossFromChangeInFairValueOfMilestoneLiability
19000
CY2022 ktra Increase Decrease In Fair Value Of Warrants Issued For Services
IncreaseDecreaseInFairValueOfWarrantsIssuedForServices
35000
CY2023 ktra Increase Decrease In Restricted Stock Units And Shares Issued For Services
IncreaseDecreaseInRestrictedStockUnitsAndSharesIssuedForServices
200000
CY2023 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1490000
CY2022 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2248000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-371000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
722000
CY2023 ktra Increase Decrease In Clinical Trial Deposits
IncreaseDecreaseInClinicalTrialDeposits
-1700000
CY2022 ktra Increase Decrease In Clinical Trial Deposits
IncreaseDecreaseInClinicalTrialDeposits
-500000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-442000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1007000
CY2023 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-423000
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
160000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11865000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20392000
CY2023 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
232000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232000
CY2023 ktra Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
1903000
CY2022 ktra Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
21569000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
43000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
74000
CY2023 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
8000
CY2022 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
8000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1852000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21635000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10245000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1243000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11780000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10537000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1535000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11780000
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Nature of operations, corporate history, and going concern and management plans</span></div></div><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Nature of operations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage therapeutics - VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Corporate history</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation ("Adgero") in which Adgero continued its existence under Delaware law and became a direct, wholly-owned subsidiary of the Company. Following the completion of the merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC ("Nasdaq") under the symbol “KTRA”.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">References to the Company refer to the Company and its wholly-owned subsidiaries.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Going concern and management plans</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">For the year ended June 30, 2023, the Company reported a loss of $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">14,649</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> and a negative cash flow from operations of $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">11,865</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">. The Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">151,375</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> and had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">1,535</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> as of June 30, 2023. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. On August 2, 2022, the Company </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">entered into a stock purchase agreement under which the Company ultimately received approximately $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">1,903</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> in net proceeds as of June 30, 2023, which is the current maximum available under the stock purchase agreement. </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">In addition, on June 28, 2023, the Company announced that it had been awarded approximately $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> million in grant funding to be received over a two year period for its REM-001 project.</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Even with the proceeds from the grant funding and the stock purchase financing, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, debt, and/or entering into strategic partnership arrangements. However, the Company’s ability to raise additional capital could be affected by various risks and uncertainties including, but not limited to, global unrest. The Company may not be able to raise</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">These consolidated financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">.</span></p>
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14649000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11865000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151375000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1535000
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1903000
CY2023 ktra Description Of Grant Funding Received
DescriptionOfGrantFundingReceived
In addition, on June 28, 2023, the Company announced that it had been awarded approximately $2.0 million in grant funding to be received over a two year period for its REM-001 project.
CY2023Q2 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
2000000.0
CY2023 ktra Clinical Trial Deposit Expense
ClinicalTrialDepositExpense
3225000
CY2023 ktra Stockholders Equity Reverse Stock Split Policy Policy Textblock
StockholdersEquityReverseStockSplitPolicyPolicyTextblock
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Reverse stock split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">On November 10, 2022, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, in order to effectuate a 1:</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock as well as its authorized shares of common stock. </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">As a result of the Reverse Stock Split, every </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein.</span></p>
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
50
CY2023 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock.
CY2022Q4 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
50
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services, the milestone payment liability, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</span></p>
CY2023 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
three to seven years
CY2023Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2023 ktra Accruals For Research And Development Expenses And Clinical Trials Policytext Block
AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicytextBlock
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Accruals for research and development expenses and clinical trials</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended June 30, 2023, and 2022, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.</span></p>
CY2023 ktra Deposits Payments
DepositsPayments
1075000
CY2023Q2 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
895000
CY2022Q2 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
803000
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 ktra Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
5065000
CY2022 ktra Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
8163000
CY2023 ktra Clinical Trial Deposit Payments
ClinicalTrialDepositPayments
1700000
CY2021Q2 ktra Property Equipment And Intangibles Assets
PropertyEquipmentAndIntangiblesAssets
150000
CY2022 ktra Accumulated Depreciation Depletion And Amortization Property Plant And Equipment And Intangibles Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAndIntangiblesAssets
60000
CY2022Q2 ktra Property Equipment And Intangibles Assets
PropertyEquipmentAndIntangiblesAssets
90000
CY2023 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
679000
CY2023 ktra Accumulated Depreciation Depletion And Amortization Property Plant And Equipment And Intangibles Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAndIntangiblesAssets
60000
CY2023Q2 ktra Property Equipment And Intangibles Assets
PropertyEquipmentAndIntangiblesAssets
709000
CY2023 us-gaap Payments For Software
PaymentsForSoftware
859000
CY2022 us-gaap Payments For Software
PaymentsForSoftware
180000
CY2023Q2 ktra Capitalized Cost Of Property And Equipment Not In Use
CapitalizedCostOfPropertyAndEquipmentNotInUse
679000
CY2023 us-gaap Depreciation
Depreciation
60000
CY2022 us-gaap Depreciation
Depreciation
60000
CY2023Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
298000
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
721000
CY2023Q2 ktra Deferred Tax Assets Financing Cost
DeferredTaxAssetsFinancingCost
326000
CY2022Q2 ktra Deferred Tax Assets Financing Cost
DeferredTaxAssetsFinancingCost
326000
CY2021Q2 ktra Milestone Payment Liability
MilestonePaymentLiability
182000
CY2022 ktra Milestone Payment Liability Change In Fair Value Estimate
MilestonePaymentLiabilityChangeInFairValueEstimate
-19000
CY2022Q2 ktra Milestone Payment Liability
MilestonePaymentLiability
163000
CY2023 ktra Milestone Payment Liability Change In Fair Value Estimate
MilestonePaymentLiabilityChangeInFairValueEstimate
3000
CY2023Q2 ktra Milestone Payment Liability
MilestonePaymentLiability
166000
CY2023 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
16000
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
110000
CY2021Q3 ktra Underwritten Public Offerings Description
UnderwrittenPublicOfferingsDescription
the Company closed on the sale of (i) 144 shares of its common stock, par value $0.001 per share, (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 96 shares of common stock and (iii) common warrants to purchase an aggregate of 240 shares of common stock (“2022 Investor Warrants”) in the Company’s registered direct offering (the “September Offering”). Each share of common stock, or PFW as applicable, was sold together with a 2022 Investor Warrant to purchase one share of common stock at a combined effective price of $62.50 per share of common stock and accompanying 2022 Investor Warrant. The 2022 Investor Warrants have been valued at $7,023 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.55%, a contractual term of 3.5 years, a volatility of 116.7%, and a dividend rate of 0%.
CY2022Q2 ktra Underwritten Public Offerings Description
UnderwrittenPublicOfferingsDescription
the Company closed on the sale of 324 shares of its common stock, par value $0.001 per share, and common warrants to purchase an aggregate of 324 shares of common stock (“2022 April Investor Warrants”) in the Company’s registered direct offering (the “April Offering”). Each share of common stock was sold together with a 2022 April Investor Warrant to purchase one share of common stock at a combined effective price of $26.50 per share of common stock and accompanying 2022 April Investor Warrant. The 2022 April Investor Warrants have been valued at $3,898 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.54%, a contractual term of 5 years, a volatility of 109.4%, and a dividend rate of 0%.
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
276000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
51.71
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
160000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
198000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
80000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1490000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2248000
CY2023Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
37000
CY2022Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
85000
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
77000
CY2021Q2 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
80.18
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
79000
CY2022 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
49.46
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
48000
CY2022 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
78.23
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
24000
CY2022 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice
83.76
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
84000
CY2022Q2 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
51.23
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
78000
CY2023 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
8.79
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
44000
CY2023 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
48.53
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
118000
CY2023Q2 ktra Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
24.12
CY2023 ktra Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P8Y9M29D
CY2022 ktra Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y2M8D
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29204000
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25541000
CY2023Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
982000
CY2022Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
635000
CY2023Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
18000
CY2022Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
18000
CY2023Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
769000
CY2022Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
690000
CY2023Q2 ktra Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
265000
CY2023Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
32496000
CY2022Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
28098000
CY2023Q2 ktra Deferred Tax Liabilities Scientific Research And Development
DeferredTaxLiabilitiesScientificResearchAndDevelopment
127000
CY2022Q2 ktra Deferred Tax Liabilities Scientific Research And Development
DeferredTaxLiabilitiesScientificResearchAndDevelopment
114000
CY2023Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32369000
CY2022Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27984000
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32369000
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27984000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3076000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4743000
CY2023 ktra Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
-1095000
CY2022 ktra Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
802000
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-127000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-345000
CY2023 ktra Income Tax Reconciliation Effect Of Foreign Exchange Rates
IncomeTaxReconciliationEffectOfForeignExchangeRates
66000
CY2022 ktra Income Tax Reconciliation Effect Of Foreign Exchange Rates
IncomeTaxReconciliationEffectOfForeignExchangeRates
445000
CY2023 ktra Income Tax Reconciliation Nondeductible Expense Benefit Research And Development
IncomeTaxReconciliationNondeductibleExpenseBenefitResearchAndDevelopment
-61000
CY2022 ktra Income Tax Reconciliation Nondeductible Expense Benefit Research And Development
IncomeTaxReconciliationNondeductibleExpenseBenefitResearchAndDevelopment
-44000
CY2023 ktra Income Tax Reconciliation Adjustment To Prior Year S Provision Versus Statutory Tax Returns
IncomeTaxReconciliationAdjustmentToPriorYearSProvisionVersusStatutoryTaxReturns
-106000
CY2022 ktra Income Tax Reconciliation Adjustment To Prior Year S Provision Versus Statutory Tax Returns
IncomeTaxReconciliationAdjustmentToPriorYearSProvisionVersusStatutoryTaxReturns
-2332000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
13000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
196000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4386000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6021000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
34100000
CY2023 ktra Percentage Of Taxable Income Limitation On No Ls
PercentageOfTaxableIncomeLimitationOnNOLs
0.80
CY2023 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
expire between 2031 and 2042
CY2023 ktra Minimum Cumulative Percentage Of Change In Ownership As Condition To Offset Taxable Income Or Tax
MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax
0.50
CY2023 ktra Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2023 ktra Remaining Commitments Related To Drug Manufacturing And Clinical Study Management And Safety
RemainingCommitmentsRelatedToDrugManufacturingAndClinicalStudyManagementAndSafety
3200000
CY2023 ktra Clinical Development Research Deposits
ClinicalDevelopmentResearchDeposits
4300000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
39000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
41400
CY2023 ktra Non Cash Issue Costs
NonCashIssueCosts
289000
CY2022 ktra Non Cash Issue Costs
NonCashIssueCosts
683000
CY2022 ktra Issue Costs In Accounts Payable
IssueCostsInAccountsPayable
43000
CY2023 ktra Equipment Additions Reclassified From Prepaid Expenses
EquipmentAdditionsReclassifiedFromPrepaidExpenses
447000
CY2022 ktra Conversion Of Series C Preferred Stock To Common Stock
ConversionOfSeriesCPreferredStockToCommonStock
2377000
CY2023 us-gaap Concentration Risk Credit Risk Financial Instrument Maximum Exposure
ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
12000
CY2023 ktra Concentration Risk Credit Risk Uninsured Amount Of Cash
ConcentrationRiskCreditRiskUninsuredAmountOfCash
957000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1535000
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
578000
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
957000

Files In Submission

Name View Source Status
0000950170-23-048588-index-headers.html Edgar Link pending
0000950170-23-048588-index.html Edgar Link pending
0000950170-23-048588.txt Edgar Link pending
0000950170-23-048588-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img139665719_0.jpg Edgar Link pending
img139665719_1.jpg Edgar Link pending
img139665719_2.jpg Edgar Link pending
img139665719_3.jpg Edgar Link pending
img139665719_4.jpg Edgar Link pending
ktra-20230630.htm Edgar Link pending
ktra-20230630.xsd Edgar Link pending
ktra-ex21_1.htm Edgar Link pending
ktra-ex23_1.htm Edgar Link pending
ktra-ex31_1.htm Edgar Link pending
ktra-ex31_2.htm Edgar Link pending
ktra-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
ktra-20230630_def.xml Edgar Link unprocessable
ktra-20230630_pre.xml Edgar Link unprocessable
ktra-20230630_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ktra-20230630_cal.xml Edgar Link unprocessable
ktra-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable